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Abstract 
Atypical antipsychotics such as olanzapine and clozapine are effective at treating the 
multiple domains of schizophrenia, with a low risk of extra-pyramidal side-effects. 
However a major downfall to their use is metabolic side-effects particularly weight 
gain/obesity, which occurs by unknown mechanisms. The present paper explores the 
potential candidature of histaminergic neurotransmission in the mechanisms of 
atypical antipsychotic-induced weight gain, with a focus on the histaminergic H1 and 
H3 receptors. Olanzapine and clozapine have a high affinity for the H1 receptor, and 
meta-analyses show a strong correlation between risk of weight gain and H1 receptor 
affinity. In addition, olanzapine treatment decreases H1 receptor binding and mRNA 
expression in the rat hypothalamus. Furthermore, a complex role is emerging for the 
histamine H3 receptor in the control of hunger. The H3 receptor is a pre-synaptic 
autoreceptor that inhibits the synthesis and release of histamine, and a heteroreceptor 
that inhibits other neurotransmitters such as serotonin (5-HT), noradrenaline (NA) and 
acetylcholine (ACh), which are also implicated in the regulation of food intake. Thus, 
the H3 receptor is in a prime position to regulate food intake, both through its control 
of histamine and its influence on other feeding pathways. We proposed that a 
mechanism for atypical antipsychotic-induced weight gain may be partly through the 
H3 receptor, as a drug-induced decrease in H1 receptor activity may decrease 
histamine tone through the H3 autoreceptors, compounding the weight gain problem. 
In addition, atypical antipsychotics may affect food intake by influencing 5-HT, NA 
and ACh release via interactions with the H3 heteroreceptor.  
 
Keywords: antipsychotic; olanzapine; clozapine; body weight gain; obesity; 
histamine receptor 
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Abbreviations: 5-HT, serotonin; α-MH, R-α-methyl-histamine; ACh, acetylcholine; 
Arc, hypothalamic arcuate nucleus; CCK, cholecystokinin; DMN, dorsal motor 
nucleus of the vagal nerve; DVC, dorsal vagal complex; H1RKO, H1 receptor 
knockout; NA, noradrenaline; NTS, nucleus of the solitary tract;  VMH, ventromedial 
hypothalamic nucleus. 
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1. Introduction 
Antipsychotic drugs play a key role in the treatment of schizophrenia and are 
increasingly prescribed for other health issues such as bipolar disorder, major 
depression, dementia and substance abuse (Centorrino et al., 2002). In addition, these 
drugs are utilized in hospital emergency departments to assist patients presenting with 
acute psychosis  (Ballerini et al., 2003).  
 
Atypical antipsychotic drugs (such as olanzapine and clozapine) are considered to 
possess superior efficacy in treating the positive, negative and cognitive domains of 
schizophrenia compared to conventional ‘typical’ antipsychotics, particularly in 
schizophrenia patients that are non-responsive to conventional drug therapy (Matza et 
al., 2005, Keefe et al., 2006). Differing to the typical profile, atypical antipsychotic 
drugs generally affect a range of receptors, including adrenergic, histaminergic, 
serotonergic and muscarinic, with less antagonistic effects on D2 receptors than 
typical antipsychotic drugs and therefore a lower propensity to cause extrapyramidal 
side-effects (Richelson and Souder, 2000, Roth et al., 2004). However, a significant 
side-effect of atypical antipsychotic drug-use is weight gain/obesity, which is of social 
and clinical importance as it may lead to further complications such as non-
compliance of medication, diabetes and cardiovascular disease. Despite this 
significance, the mechanisms behind atypical antipsychotic-induced weight gain 
remain unclear, perhaps because these drugs differ markedly in their pharmacological 
profiles, and because of the complex and well-preserved interactions between the 
systems involved in energy balance regulation. Understanding the mechanisms 
causing this side-effect will help to improve future pharmacotherapies for 
schizophrenia, as patients commonly undergo many years of drug treatment due to the 
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chronicity of the disease. The present paper explores the potential candidature of 
histaminergic neurotransmission in the mechanisms of atypical antipsychotic-induced 
weight gain, with a focus on the histaminergic H1 and H3 receptors. We propose that 
the H3 receptor may impact histaminergic H1 signaling, as well as other 
neurotransmitter systems such as the serotonergic, noradrenaline and acetylcholine 
pathways, to influence body energy balance regulation. 
 
2. Methods 
A reference search was performed across the Medline (January 1996-May 2009) and 
ScienceDirect (January 1995-May 2009) databases. Key words included atypical 
antipsychotic, individual drug names (clozapine, olanzapine, risperidone, aripiprazole, 
quetiapine, and ziprasidone), histamine, and histamine receptor, cross-referenced with 
weight gain, obesity, and food intake. In addition, the reference list of all papers 
identified was reviewed.  
 
3. Weight Gain Side-Effect of Olanzapine and Clozapine treatment 
Olanzapine is an atypical antipsychotic drug commonly used in the clinical setting 
due to its efficacy and tolerability in the treatment of the multiple domains of 
schizophrenia (Keefe et al., 2006, Haro et al., 2009). However, olanzapine and other 
atypical antipsychotic drugs such as clozapine can induce significant weight gain and 
further metabolic disorders including insulin resistance, diabetes and lipid metabolism 
dysfunction. Among antipsychotics, olanzapine has a higher risk for weight gain than 
the conventional antipsychotics haloperidol, chlorpromazine and fluphenazine, and its 
atypical counterparts risperidone, aripiprazole, sertindole, thioridazine, quetiapine, 
amisulpride, zotepine and ziprasidone (Allison et al., 1999, Nasrallah, 2008). 
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Clozapine, which is also effective for use against treatment-resistant schizophrenia, 
may induce more weight than olanzapine (4.45kg and 4.15kg, respectively over 10-
weeks) (Allison et al., 1999), however a recent study found that high dosages of 
olanzapine (mean dosage 34mg/day) induced significantly higher weight gain than 
clozapine (+5.6 ±2.0 kg olanzapine vs clozapine, mean dosage 564mg/day, after 6-
months treatment) in patients with treatment-resistant schizophrenia (Meltzer et al., 
2008). Another study found that patients gained 9.2kg within the first 12 weeks of 
olanzapine treatment (dosage range 5-20mg/day), and 15.5kg after 52 weeks, 
plateauing to 15.4kg after 2 years (Zipursky et al., 2005).  
 
The broad receptor binding profile exhibited by olanzapine, clozapine and other 
atypical antipsychotic drugs may underlie the cause of this weight-gain side-effect, as 
evidence suggests a role for some of these signaling pathways in obesity. In 
particular, the histaminergic system is well-documented for its importance in the 
control of food intake (Yoshimatsu, 2006). However, there appears to be a limited 
understanding of the effects of weight-inducing atypical antipsychotics on central 
histaminergic signaling, despite evidence identifying these neurotransmitter pathways 
as potential targets to assist the current understanding of the mechanisms of atypical 
antipsychotic-induced weight gain.  
 
4. Histamine and Body Weight Regulation 
A vast body of evidence shows the importance of central histamine signaling in the 
control of food intake and energy regulation (Yoshimatsu et al., 2002, Yoshimatsu, 
2006). Histamine neurons are located in the tuberomamillary nucleus of the posterior 
hypothalamus and project axons throughout most of the brain, with particularly strong 
                                                                                                                                7 
innervation in the hypothalamus (Brown et al., 2001). Histamine depolarises select 
brainstem neurons in the nucleus of the solitary tract (NTS) and dorsal motor nucleus 
of the vagal nerve (DMN) in the dorsal vagal complex (DVC) (Poole et al., 2008), 
which together with the hypothalamus, have a fundamental role in the control and 
regulation of food intake (Arora and Anubhuti, 2006, Jelsing et al., 2009).   
 
5. Histamine H1 and H3 Receptors and Body Weight Regulation 
Histamine exerts its effects through histamine H1, H2, H3 and H4 receptors (Masaki 
and Yoshimatsu, 2006). The histamine H1 receptor has long been target of interest in 
the regulation of food intake. Intracerebroventricular application of a histamine H1 
receptor agonist (2-(3-trifluoromethylpehenyl)histamine) potently suppresses food 
intake, whilst hypothalamic H1 receptor antagonism results in food intake (Sakata et 
al., 1997, Han et al., 2008). H1 receptor knockout (H1RKO) mice develop obesity 
accompanied by increased food intake, altered diurnal feeding patterns, and a 
decrease in uncoupling protein-1 mRNA expression (Masaki et al., 2004).  
 
In addition to the H1 receptor, the histamine H3 receptor is implicated in the control 
of food intake. For example, H3 receptor angatonism in the hypothalamus reduces 
food intake and induces weight loss in diet-induced obese rodents, as well as rhesus 
monkeys and pigs (Hancock et al., 2004, Malmlof et al., 2005, Malmlöf et al., 2007), 
whilst the H3 agonist, immepip enhances feeding in rats (Chiba et al., 2009). In 
addition, H3 receptor knock-out mice (H3RKO) exhibit increased body weight gain, 
food intake and adiposity, coupled with decreased energy expenditure, insulin and 
leptin resistance, as well as increased histamine turnover therefore decreased 
hypothalamic histamine levels (Takahashi et al., 2002). Furthermore, the H3 
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receptor’s localisation in the hypothalamus and NTS of the DVC is supportive of its 
potential role in the regulation of food intake (Poole et al., 2008).  
 
The histamine H3 receptor has a distinct role in numerous appetite signalling 
pathways. For example, the H3 receptor inverse agonist, thioperamide, inhibits food 
intake induced by the potent orexigen neuropeptide Y and its structural relative, 
peptide YY (Itoh et al., 1999), whilst H3 receptor agonists, R-α-methyl-histamine (α-
MH) and Imetit, decrease bombesin-induced satiety in rats (Kent et al., 1997). In 
addition, H3 receptor activation reduces the anorexigenic effects of amylin in fasted 
rats (Lutz et al., 1996). Similarly, a study by Attoub and colleagues (2001) found that 
α-MH dose-dependently inhibited the satiating effects of cholecystokinin (CCK), 
whilst thioperamide enhanced CCK-induced satiety. They also found that pre-
treatment with pyrilamine, a post-synaptic H1 receptor antagonist, inhibited CCK-
induced satiety (Attoub et al., 2001), indicating that whilst H3 controls pre-synaptic 
histamine concentrations, CCK-induced satiation is also dependent upon the post-
synaptic activation of the H1 receptor. Although it is clear that the H3 receptor plays 
an important role in regulating food intake, the question of how weight-inducing 
atypical antipsychotic drugs affect H3 receptor neurotransmission appears to be 
largely unanswered. 
 
6. Histaminergic mechanisms for atypical antipsychotic-induced weight gain 
6.1 A role for the H1 receptor 
The severity of weight gain induced by an antipsychotic drug may be predicted by its 
H1 antagonistic properties. In fact, a meta-analyses by two groups, (Kroeze et al., 
2003, Matsui-Sakata et al., 2005) found significant strong correlations between 
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antipsychotic H1 receptor affinity and antipsychotic-induced weight gain. For 
example, olanzapine is a potent H1 receptor antagonist, whereas haloperidol, an 
antipsychotic with a low propensity to increase body weight, has a low affinity for H1 
receptors (Richelson and Souder, 2000). A recent study from our laboratory found 
that acute (1-week) and chronic (12-weeks) olanzapine treatment significantly down-
regulated H1 receptor mRNA expression in the hypothalamic arcuate (Arc) and 
ventromedial nucleus (VMH), but not haloperidol or aripiprazole, antipsychotics with 
a lower risk of weight gain side-effect (Han et al., 2008). In addition, olanzapine 
decreased H1 receptor binding density in the VMH. This altered H1 signaling was 
accompanied by an increase in food intake and weight gain in olanzapine-treated rats 
compared to those treated with aripiprazole or haloperidol (Han et al., 2008). 
Coinciding with the findings from our laboratory, a study by Kim and colleagues 
(2007) found that olanzapine and clozapine activate hypothalamic AMP-protein 
kinase (AMPK), which increases food intake and weight gain (Minokoshi et al., 
2004), via H1 receptor antagonism. Taken together, these findings suggest that a 
possible mechanism for atypical antipsychotic-induced weight gain is through a drug-
induced decrease in the hypothalamic expression of the H1 receptor, blockade of 
which is linked to downstream AMPK activation, resulting in increased food intake 
(Figure 1) that, when coupled with an insufficient increase in locomotor activity, 
contributes to weight gain (Kim et al., 2007, Han et al., 2008).  
 
6.2 A possible role for the H3 receptor 
The effect of weight-inducing atypical antipsychotic drugs on H3 receptors in the 
brain appears to be unknown. It is possible that the olanzapine-induced decrease in 
post-synaptic H1 receptors observed by our early study (Han et al., 2008) would result 
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in an increase in synaptic histamine, which may slowdown histamine synthesis and 
secretion through the H3 autoreceptor, compounding the enhancement of feeding 
behaviour (Figure 1) (Takahashi et al., 2002, Chiba et al., 2009). Supporting this 
hypothesis, Lozeva and colleagues (2003) found that acute (1-week) enhanced central 
histamine concentrations, induced by L-histidine loading, increased H3 receptor 
expression in some regions of the rat brain, excluding the hypothalamus. However, 
the absence of an increase in hypothalamic H3 receptor binding following L-histidine 
loading after 1-week may be attributed to the short treatment period, as chronic over-
exposure to an agonist can significantly alter the intracellular distribution of these G-
protein-coupled receptors (Koenig and Edwardson, 1997). Coinciding with this idea, 
Poyurovsky and colleagues (2005) evaluated the weight-attenuating effects of β-
histidine (a potent H3 antagonist and weak H1 agonist) on olanzapine-induced weight 
gain in a small group of schizophrenia patients. β-histidine has been shown with an 
effect to inhibit food intake in rats (Szelag et al., 2001). Through co-administration of 
olanzapine with β-histidine for 6-weeks, schizophrenia patients showed a weight 
increase during the initial 2 weeks of the trail with no additional weight gain or a 
minor reduction of body weight from weeks 3 to 6. This delayed response of β-
histidine on curbing and controlling olanzapine-induced weight gain suggests its 
marked antagonist effect on pre-synaptic H3 receptors, rather than the direct but weak 
agonist effect on post-synaptic H1 receptor (Poyurovsky et al., 2005). In addition, a 
study by Lacour and Sterkers (2001) found that 1-week treatment with β-histidine 
decreased the binding density of the H3 receptor, whilst 3-weeks treatment resulted in 
an increase in H3 binding in the cat brain. Taken together, these studies provide 
evidence that examination of H3 binding alterations in a chronic setting may be more 
representative of the clinical application of weight-inducing antipsychotic drugs. 
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It is also important to consider that H3 heteroreceptor activity may also play a role in 
atypical antipsychotic-induced weight gain. The H3 heteroreceptors are located on 
pre-synaptic axon terminals of serotonin (5-HT), noradrenaline (NA), and 
acetylcholine (ACh) neurons, where they regulate neurotransmitter release (Pollard et 
al., 1993, Arrang et al., 1995, Leurs et al., 1998). It has been reported that the H3 
heteroreceptors inhibits serotonin release (5-HT), which results in an increase in food 
intake (Cole et al., 1998). In fact, the clinical efficacy of the anti-obesity drugs, 
fenfluramine and sibutramine, can be attributed to their ability to enhance 5-HT 
availability (Cole et al., 1998, Tallett et al., 2009). Also, the antihistamines 
cyproheptadine and promethazine are non-selective 5-HT receptor antagonists, in 
addition to their potency as histamine receptor blockers, that induce food-intake and 
weight gain in humans and rats (Yoshimatsu et al., 2002). 
 
Clozapine has been shown to posses moderately low H3 receptor antagonistic 
properties (Schlicker and Marr, 1996), which may be contrary to its weight-gain 
liability in an acute treatment setting. However, antagonism of the H3 heteroreceptor 
has been shown to disinhibit neurotransmitter release (Arrang et al., 1995), which in 
the case of H3 heteroreceptors located on NA and ACh neurons, may account for the 
side-effect of atypical antipsychotic-induced food intake (Figure 1), as studies show 
that NA and ACh can act as orexigens to increase food intake (Kurose and Terashima, 
1999, Pratt and Blackstone, 2009). Furthermore, secretion of these neurotransmitters 
is inhibited by the activation of H3 receptors (Arrang et al., 1995), whilst H3 
antagonism disinhibits the release of these neurotransmitters. 
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7. Conclusion:  
Atypical antipsychotic drugs, such as olanzapine and clozapine, are commonly used 
in the clinical setting due to their efficacy in treating the multiple domains of 
schizophrenia. However, these drugs cause weight gain/obesity and other metabolic 
side-effects such as diabetes and dyslipidaemia, which occur by unknown 
mechanisms. The histaminergic system is well-documented for its involvement in 
reducing food intake through the histamine-induced activation of the H1 receptor. 
Olanzapine and clozapine have a high affinity for the H1 receptor and olanzapine 
treatment has been shown to decrease H1 receptor binding density and mRNA 
expression in the hypothalamus. The histamine H3 receptor also plays an important 
role in food intake and body weight. It acts as a pre-synaptic autoregulator of 
histamine synthesis and release, as well as a heteroreceptor for numerous other 
neurotransmitter signalling pathways, some of which are implicated in the regulation 
of feeding behaviour. However, the effect of weight-inducing antipsychotic drugs on 
the H3 receptor is unknown. In the present review, we proposed that the weight gain 
side-effect of some atypical antipsychotic drugs may be partly through an effect on 
the H3 receptor, compounding the weight gain side-effect. In addition, weight-
inducing antipsychotic drugs may increase food intake by affecting the H3 
heteroreceptor, which influences 5-HT, NA and ACh release.  
 
Both H1 and H3 receptors appear to be good candidates to enhance the current 
understanding of the mechanisms of atypical antipsychotic-induced weight gain. In 
addition, obesity is a non-discriminatory and serious public problem, and 
understanding the mechanisms behind antipsychotic-induced weight gain may also 
help to unravel the pathophysiology of obesity in the general population.  
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Figure 1 Proposed mechanisms of atypical antipsychotic-induced weight gain through 
histaminergic H1 and H3 receptors. Olanzapine and clozapine can block H1 
receptors and decrease H1 receptor density in the ventromedial nucleus 
(VMH), activating AMP-protein kinase (AMPK), which increases food intake 
and weight gain. An olanzapine-induced decrease in post-synaptic H1 
receptors may result in an increase in synaptic histamine, which activates the 
pre-synaptic H3 autoreceptor, slowing histamine synthesis and secretion and 
compounding hyperphagic behaviour. Clozapine (with some H3 antagonistic 
properties) may act on H3 heteroreceptors to disinhibit acetylcholine (ACh) 
and noradrenaline (NA) release, which may enhance food intake. Although 
antagonistic effects on H3 heteroreceptors may increase 5-HT release, which 
decreases food intake, these antipsychotics are also 5-HT receptor antagonists 
which can induce food intake and weight gain. Taken together, the H3 
receptor may act as an auto- or hetero-receptor to mediate complex 
interactions between numerous neurotransmitter systems to induce 
hyperphagia and body weight gain.  
 
